Swipe Left For English News
新加坡,
2024年3月21日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）今日宣布，公司在“2024亚太生物工艺卓越奖”（ABEA）颁奖典礼上斩获四项大奖，药明生物全球生物制药开发及运营总裁、首席技术官周伟昌博士荣膺2023年 “年度首席技术官”。药明生物自2017年起已连续多年在该评选中获奖，今年摘得的奖项数目创下历史新高：
ABEA是由生物制药领域专业咨询公司IMAPAC主办的行业评选，旨在表彰生物制药公司、领军人物或前沿洞察者的杰出成就与实践，以此激励行业中涌现层出不穷的创新者。
药明生物凭借前沿创新技术、国际一流的质量管理体系、强大的全球生产网络和卓越的生产成功率，为全球近600个客户提供一体化端到端服务，不断赋能客户将创新生物药推进到临床并成功上市。
值得一提的是，药明生物国际领先的生物制剂GMP生产已获全球主要药品监管机构认证，包括美国食品药品监督管理局（FDA）、欧洲药品管理局（EMA）以及中国国家药品监督管理局（NMPA），并已成功通过逾1000次全球客户的质量审计。公司已完成超过1700批次生物制剂生产，成功率高达99%以上，彰显公司优于业界的生产水平和质量水平。
陈智胜博士
首席执行官
药明生物
药明生物斩获多项大奖，充分体现了客户以及行业对我们所创造价值的认可，这些成就离不开我们凝心聚力的领导团队和优秀人才。我们始终坚守严苛的质量标准和卓越的执行力，将持续赋能客户加速创新生物药惠及全球患者。
此次颁奖典礼上，周伟昌博士凭借出色的领导力以及在生物制药开发及生产领域的开拓性成就，荣获“年度首席技术官”称号。
周伟昌博士
全球生物制药开发及运营总裁，首席技术官
药明生物
获得此项殊荣，我深感荣幸。多年来，我和公司团队始终以极大的热情投身于生物制药技术创新，不断拓展技术平台的灵活性，努力提高研发和生产的效率及产能，为提升创新生物药的可及性和可负担性做出贡献。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年12月底，药明生物帮助客户研发和生产的综合项目高达698个，其中包括24个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
媒体关系 PR@wuxibiologics.com
业务垂询 info@wuxibiologics.com
WuXi Biologics Wins Four Asia-Pacific Biopharma Excellence Awards;
Dr. Weichang Zhou Honored with CTO of the Year 2023
Singapore,
March 21, 2024
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it received four awards at the 2024 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony, and that the company's President of Global Biologics Development and Operations and Chief Technology Officer (CTO), Dr. Weichang Zhou, was honored with CTO of the Year 2023.
WuXi Biologics stood out in the following categories, achieving its highest number of awards since first receiving ABEA recognition in 2017:
Sponsored by IMAPAC, a leading consulting firm in the biopharmaceutical industry, the ABEA seeks to recognize the outstanding achievements of top leaders in biomanufacturing, biologistics and clinical trials, applauding extraordinary leaders and trend-setters of today and inspiring innovators of tomorrow.
WuXi Biologics provides end-to-end services for nearly 600 clients worldwide. With its innovative technologies, world-class quality systems, extensive global manufacturing network and proven success rates, the company enables clients to advance their biologics into the clinic and on to the market.
The company's drug product GMP manufacturing services have been validated by major regulatory agencies, including the FDA, EMA and China NMPA, as well as by over 1,000 quality audits from global clients. An overall success rate of 99%+ has been achieved for more than 1,700 batches of drug products.
Dr. Chris Chen
CEO
WuXi Biologics
The multiple awards WuXi Biologics received are a true testament to the value we have created for our clients and for the industry. With an unwavering commitment to excellence and quality, a strong leadership team and dedicated people, we will continue to enable our clients to accelerate breakthrough treatments to benefit patients worldwide.
Dr. Weichang Zhou won CTO of the Year award for his remarkable leadership and achievements in pioneering technology innovations to expedite biologics development and manufacturing.
Dr. Weichang Zhou
President of Global Biologics Development and Operations
CTO
WuXi Biologics
I am honored to receive this award. It is exciting to be part of the advancement of more flexible, productive, and efficient approaches as our team at WuXi Biologics works to enhance technologies that help increase the global accessibility and affordability of biologic therapies.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Business
Info@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
